Status: current, Sufficiently defined by necessary conditions definition status. Date: 31-Aug 2022. Module: SNOMED CT core module
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 5097894011 | Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | en | Fully specified name | Active | Entire term case insensitive | SNOMED CT core module |
| 5097895012 | Levocetirizine dihydrochloride 2.5 mg and montelukast (as montelukast sodium) 4 mg tablet for oral suspension | en | Synonym | Active | Entire term case insensitive | SNOMED CT core module |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Is a | Product containing only levocetirizine and montelukast in oral dose form (medicinal product form) | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has manufactured dose form | Dispersible tablet | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has unit of presentation | Tablet | true | Inferred relationship | Existential restriction modifier | ||
| Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has precise active ingredient | Montelukast sodium | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has basis of strength substance | Montelukast | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has presentation strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Existential restriction modifier | 1 | |
| Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has precise active ingredient | Levocetirizine dihydrochloride | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has basis of strength substance | Levocetirizine dihydrochloride | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has presentation strength numerator unit | milligram | true | Inferred relationship | Existential restriction modifier | 2 | |
| Product containing precisely levocetirizine dihydrochloride 2.5 milligram and montelukast (as montelukast sodium) 4 milligram/1 each tablet for conventional release oral suspension (clinical drug) | Has presentation strength denominator unit | Tablet | true | Inferred relationship | Existential restriction modifier | 2 |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR